3D Printing Scaffold Vaccine for Antitumor Immunity
Source abstract
Abstract
Abstract Cancer vaccine platform has attracted great interest in the field of cancer immunotherapy. Here, 3D printed scaffolds loaded with immunoregulators are developed for enhanced cancer immunotherapy. The rapid manufacturing and precise molding based on 3D printing can realize the mass manufacturing of cancer vaccines and personalized design. Meanwhile, compared to the traditional hydrogel, the 3D‐scaffold with porous structure endows its similar functions compared with real lymphoid organs by recruitment of a great number of immune cells, leading to the formation of “artificial tertiary lymphoid structures,” where there is a promising site to enhance both humoral and cellular immune responses. Efficient anticancer immunity is induced when combined with immune checkpoint blockade to inhibit the tumor growth. Personalized antitumor scaffold vaccines are further demonstrated for filling of tumor site after surgery to prevent cancer metastasis. Taken together, these results promise the 3D printing scaffold vaccine as the potential strategy for cancer vaccine therapy in the future.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Immunotherapy and Immune Responses · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Functional Nano and Soft Materials (FUNSOM) Jiangsu Key Laboratory for Carbon‐Based Functional Materials and Devices Soochow University Suzhou Jiangsu 215123 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · Collaborative Innovation Center of Suzhou Nano Science and Technology · Priority Academic Program Development of Jiangsu Higher Education Institutions
References (35)
Show source-provided references
1. 10.1016/j.canlet.2017.04.02410.1016/j.canlet.2017.04.024 ↗
2. 10.1039/c3cs60141b10.1039/c3cs60141b ↗
3. 10.1002/1878-0261.1273110.1002/1878-0261.12731 ↗
4. Zhou J. R. · Adv. Mater. · 2020 · 32 · 22
5. 10.1038/s41586-020-2537-910.1038/s41586-020-2537-9 ↗
6. 10.1038/s41585-020-0282-310.1038/s41585-020-0282-3 ↗
7. 10.1126/science.aau044710.1126/science.aau0447 ↗
8. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
9. 10.1002/anie.20180488210.1002/anie.201804882 ↗
10. 10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
11. 10.3389/fimmu.2020.58274410.3389/fimmu.2020.582744 ↗
12. 10.1126/scitranslmed.aaz357710.1126/scitranslmed.aaz3577 ↗
13. 10.1093/annonc/mdy55110.1093/annonc/mdy551 ↗
14. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
15. Fan Q. · Sci. Adv. · 2020 · 6 · 12
16. 10.1038/s41557-020-0426-310.1038/s41557-020-0426-3 ↗
17. 10.1016/j.actbio.2019.08.01310.1016/j.actbio.2019.08.013 ↗
18. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
19. 10.1016/j.bioactmat.2020.09.00110.1016/j.bioactmat.2020.09.001 ↗
20. 10.1016/j.bioactmat.2020.07.00710.1016/j.bioactmat.2020.07.007 ↗
21. 10.1038/s41578-020-0204-210.1038/s41578-020-0204-2 ↗
22. 10.1016/j.mser.2020.10054310.1016/j.mser.2020.100543 ↗
23. 10.1080/17452759.2020.171945710.1080/17452759.2020.1719457 ↗
24. 10.1002/adma.20190202610.1002/adma.201902026 ↗
25. 10.1021/acs.chemrev.5b0030310.1021/acs.chemrev.5b00303 ↗
26. 10.1021/acsami.7b1980810.1021/acsami.7b19808 ↗
27. 10.1021/acs.chemrev.9b0083410.1021/acs.chemrev.9b00834 ↗
28. 10.1088/1758-5090/8/4/04500210.1088/1758-5090/8/4/045002 ↗
29. Lee S. · Adv. Mater. · 2020 · 32 · 10
30. 10.7150/thno.3057710.7150/thno.30577 ↗
31. 10.1002/adfm.20200105910.1002/adfm.202001059 ↗
32. 10.1016/j.biomaterials.2018.01.00410.1016/j.biomaterials.2018.01.004 ↗
33. 10.3171/2016.11.JNS1649810.3171/2016.11.JNS16498 ↗
34. 10.1002/advs.20170084810.1002/advs.201700848 ↗
35. 10.1038/s41467-017-02416-010.1038/s41467-017-02416-0 ↗